A study on recombinant thrombomodulin alfa in patients with disseminated intravascular coagulation (DIC) caused by sepsis receiving continuous hemodiafiltration (CHDF).

A study on recombinant thrombomodulin alfa in patients with disseminated intravascular coagulation (DIC) caused by sepsis receiving continuous hemodiafiltration (CHDF). - A study on recombinant thrombomodulin for septic DIC patients receiving CHDF.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004074

Enrollment

Registered

2010-09-01

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disseminated intravascular coagulation (DIC)

Interventions

rTM is administered at at a dose of 380 U/kg/day for 6 days. rTM is administered at at a dose of 130 U/kg/day for 6 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. DIC patients with the first administration of rTM. 2. Septic patients who will receive CHDF for 24 hours or more after administration of rTM. 3. Written informed consent of participation.

Exclusion criteria

Exclusion criteria: 1. Chronic kidney disease 2. Patients showing intracranial, pulmonary or gastrointestinal hemorrhage. 3. Patients with a history of hypersensitivity to rTM. 4. Pregnant women, nursing mothers or possibly pregnant women. 5. Other patients judged to be inappropriate at the discretion of investigators.

Design outcomes

Primary

Measure	Time frame
Plasma levels of soluble thrombomodulin	—

Secondary

Measure	Time frame
Course of DIC score; Course of blood clotting test findings; Course of SOFA score; Course of cytokine levels; Outcome of subjects; Adverse events; Adverse drug reaction	—

Countries

Japan

Contacts

Public ContactSetoguchi Daisuke

Chiba University Graduate School of Medicine Department of Emergency and Critical Care Medicine

iki_saikou@hotmail.co.jp043-226-2372

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026